1 |
Xue JM, Astère M, Zhong MX, et al. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis[J]. Onco Targets Ther, 2018 (11): 6119-6128.
|
2 |
Sun D, Hou H, Zhang C, et al. The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis[J]. Onco Targets Ther, 2018 (11): 6539-6554.
|
3 |
Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome[J]. Oncologist, 2011, 16 (10): 1469-1478.
|
4 |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 201-6[J]. CA Cancer J Clin, 2016, 66 (1): 7-30.
|
5 |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (2): 115-132.
|
6 |
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29 (Suppl 4): iv192-iv237.
|
7 |
杨林,赵晓红,杨云梅.非小细胞肺癌治疗的新进展[J/CD].中华危重医学杂志(电子版),2017,10(6):416-420.
|
8 |
Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study[J]. J Clin Oncol, 2018, 36 (17): 1675-1684.
|
9 |
Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J]. Cell, 2018, 175 (2): 313-326.
|
10 |
Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016 (60): 190-209.
|
11 |
Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy[J]. Clin Cancer Res, 2016, 22 (16): 4023-4029.
|
12 |
Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28 (Suppl 4): iv119-iv142.
|
13 |
Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372 (26): 2521-2532.
|
14 |
Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management[J]. Am J Clin Dermatol, 2000, 1 (4): 225-234.
|
15 |
Chren MM, Lasek RJ, Sahay AP, et al. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases[J]. J Cutan Med Surg, 2001, 5 (2): 105-110.
|
16 |
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use[J]. Clin Exp Dermatol, 1994, 19 (3): 210-216.
|
17 |
Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI)[J]. J Investig Dermatol Symp Proc, 2004, 9 (2): 169-180.
|
18 |
Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity[J]. Med Care, 1996, 34 (3): 220-233.
|
19 |
王海棠,任利民,刘瑶,等. SF-12健康调查量表的评价研究现状[J].中华全科医师杂志,2015,14(7):574-576.
|